This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kurtz, M. B. Articles by Armstrong, D. Search for Related Content PubMed PubMed Citation Articles by Kurtz, M. B. Articles by Armstrong, D.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Aug 1995, 1784-1789, Vol 39, No. 8
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Aerosol and parenteral pneumocandins are effective in a rat model of pulmonary aspergillosis

MB Kurtz, EM Bernard, FF Edwards, JA Marrinan, J Dropinski, CM Douglas and D Armstrong
Merck Research Laboratories, Rahway, New Jersey 07065, USA.

The pneumocandins are semisynthetic analogs of echinocandin-like compounds that have shown efficacy in animal models of systemic candidiasis, disseminated aspergillosis, and pneumocystis pneumonia. However, the most common form of Aspergillus infection in susceptible patients is pulmonary aspergillosis, which was not directly tested in the mouse models used in the past. We have evaluated three pneumocandins, L-693,989, L-731,373, and L-733,560, in a rat model of pulmonary aspergillosis. Male Sprague-Dawley rats were treated for 2 weeks with cortisone and tetracycline and fed a low-protein diet before being inoculated via the trachea with 10(6) conidia of Aspergillus fumigatus H11-20. In the absence of drug treatment, the animals developed a progressive, rapidly fatal bronchopneumonia. All three pneumocandins at doses of 5 mg/kg (intraperitoneally [i.p.] every 12 h [q12h]) were effective in delaying mortality in this model. Survival at day 7 postinfection was 20% among controls (n = 10 for all groups), while it was 60, 80, and 90% in groups that were treated with L- 693,989, L-731,373, and L-733,560, respectively. In another trial, survival at day 7 postinfection was 25% among controls (n = 8 for all groups); it was 87.5% in a group treated with amphotericin B (0.5 mg/kg i.p. q12h) and was 100% in a group treated with L-733,560 (0.625 mg/kg i.p. q12h). In a separate trial, aerosol L-693,989 administered 2 h before infection (5 mg/kg) delayed mortality. Eight of the 10 animals treated with aerosol L-693,989 survived for 7 days, whereas only 2 of 10 control animals survived.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

• Wong-Beringer, A., Lambros, M. P., Beringer, P. M., Johnson, D. L. (2005). Suitability of Caspofungin for Aerosol Delivery: Physicochemical Profiling and Nebulizer Choice. Chest 128: 3711-3716 [Abstract] [Full Text]  
• Sanguinetti, M., Posteraro, B., Pagano, L., Pagliari, G., Fianchi, L., Mele, L., La Sorda, M., Franco, A., Fadda, G. (2003). Comparison of Real-Time PCR, Conventional PCR, and Galactomannan Antigen Detection by Enzyme-Linked Immunosorbent Assay Using Bronchoalveolar Lavage Fluid Samples from Hematology Patients for Diagnosis of Invasive Pulmonary Aspergillosis. J. Clin. Microbiol. 41: 3922-3925 [Abstract] [Full Text]  
• Nascimento, A. M., Goldman, G. H., Park, S., Marras, S. A. E., Delmas, G., Oza, U., Lolans, K., Dudley, M. N., Mann, P. A., Perlin, D. S. (2003). Multiple Resistance Mechanisms among Aspergillus fumigatus Mutants with High-Level Resistance to Itraconazole. Antimicrob. Agents Chemother. 47: 1719-1726 [Abstract] [Full Text]  
• Osherov, N., May, G. S., Albert, N. D., Kontoyiannis, D. P. (2002). Overexpression of Sbe2p, a Golgi Protein, Results in Resistance to Caspofungin in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 46: 2462-2469 [Abstract] [Full Text]  
• Bowman, J. C., Abruzzo, G. K., Anderson, J. W., Flattery, A. M., Gill, C. J., Pikounis, V. B., Schmatz, D. M., Liberator, P. A., Douglas, C. M. (2001). Quantitative PCR Assay To Measure Aspergillus fumigatus Burden in a Murine Model of Disseminated Aspergillosis: Demonstration of Efficacy of Caspofungin Acetate. Antimicrob. Agents Chemother. 45: 3474-3481 [Abstract] [Full Text]  
• Cruz, M. C., Goldstein, A. L., Blankenship, J., Del Poeta, M., Perfect, J. R., McCusker, J. H., Bennani, Y. L., Cardenas, M. E., Heitman, J. (2001). Rapamycin and Less Immunosuppressive Analogs Are Toxic to Candida albicans and Cryptococcus neoformans via FKBP12-Dependent Inhibition of TOR. Antimicrob. Agents Chemother. 45: 3162-3170 [Abstract] [Full Text]  
• Kohler, S., Wheat, L. J., Connolly, P., Schnizlein-Bick, C., Durkin, M., Smedema, M., Goldberg, J., Brizendine, E. (2000). Comparison of the Echinocandin Caspofungin with Amphotericin B for Treatment of Histoplasmosis following Pulmonary Challenge in a Murine Model. Antimicrob. Agents Chemother. 44: 1850-1854 [Abstract] [Full Text]  
• Singh, N. (2000). Invasive mycoses in organ transplant recipients: controversies in prophylaxis and management. J Antimicrob Chemother 45: 749-755 [Full Text]  
• Maesaki, S., Hossain, M. A., Miyazaki, Y., Tomono, K., Tashiro, T., Kohno, S. (2000). Efficacy of FK463, a (1,3)-beta -D-Glucan Synthase Inhibitor, in Disseminated Azole-Resistant Candida albicans Infection in Mice. Antimicrob. Agents Chemother. 44: 1728-1730 [Abstract] [Full Text]  
• Tawara, S., Ikeda, F., Maki, K., Morishita, Y., Otomo, K., Teratani, N., Goto, T., Tomishima, M., Ohki, H., Yamada, A., Kawabata, K., Takasugi, H., Sakane, K., Tanaka, H., Matsumoto, F., Kuwahara, S. (2000). In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi. Antimicrob. Agents Chemother. 44: 57-62 [Abstract] [Full Text]  
• De Lucca, A. J., Walsh, T. J. (1999). Antifungal Peptides: Novel Therapeutic Compounds against Emerging Pathogens. Antimicrob. Agents Chemother. 43: 1-11 [Full Text]